Modality
Multispecific
MOA
PI3Ki
Target
USP1
Pathway
Tau
GISTPBCET
Development Pipeline
Preclinical
Dec 2019
→ Dec 2028
PreclinicalCurrent
NCT05673282
1,628 pts·GIST
2020-06→2028-12·Not yet recruiting
NCT03011137
1,623 pts·GIST
2019-12→2028-05·Recruiting
3,251 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-022.1y awayInterim· GIST
2028-12-262.7y awayInterim· GIST
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2028-05-02 · 2.1y away
GIST
Interim
2028-12-26 · 2.7y away
GIST
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05673282 | Preclinical | GIST | Not yet recr... | 1628 | LiverFat |
| NCT03011137 | Preclinical | GIST | Recruiting | 1623 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Semainavolisib | Krystal Biotech | Phase 2 | B7-H3 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |